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Oral dispersible tablets (ODTs) are patient friendly 
dosage form that rapidly disintegrate or dispersed in 
mouth without the need of water
1
. The requirements for 
delivering drugs to patients efficiently with minimum 
side effects have provoked pharmaceutical industries to 
be involved in development of new drug delivery 
systems. The oral route of drug administration is the 
most and convenient way for patient regarding use of 
medications. Novel oral drug delivery systems that 
dissolve or disperse quickly in a few seconds after 
placement in the mouth without water can solve the 
problem of swallowing tablets
2
. An orally disintegrating 
tablet or orodispersible tablet (ODT) is a drug dosage 
form available for a limited range of over-the-counter 
(OTC) and prescription medications. ODTs differ from 
traditional tablets in that they are designed to be 
dissolved on the tongue rather than swallowed whole. 
Among all the routes of drug administration, the oral 
route of administration of drug is the most preferred 
route because of lot of advantages including ease of 
ingestion, avoidance of pain, versatility and patient 
compliance.  But the common drawback of tablets and 
capsules dosage forms for paediatric and geriatric 
patients is difficulty in swallowing. Most of the general 
population, especially the elderly patients and children 
suffer from dysphasia which results in high occurrence 
of noncompliance and ineffective treatment. Swallowing 
problems also are very common in young individuals 
because of their poorly developed muscular and nervous 
systems
3
. Other groups who may experience problems in 
swallowing conventional oral dosage forms are the 
patients with tremors of extremities, mentally ill, 
developmentally disabled, non co-operative patients and 
patients with reduced liquid intake plans or patients 
suffering from nausea. The swallowing problems are 
also common in some cases such as patients with motion 
sickness, sudden episodes of allergic attack or coughing 
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ABSTRACT: 
Mostly the drugs are administered by oral route. Orally dispersible tablets are achieving importance when compared to 
novel oral drug delivery system. Orodispersible tablets are suitable for all age patients by masking the taste of drug. The 
objective of the present study was to optimize, formulate and evaluate orally dispersible tablet (ODT) of Paracetamol which 
disintegrates within few seconds in presence of saliva fluid by the use of super disintegrants.  Paracetamol is widely used 
over-the counter analgesic (pain reliever) and antipyretic (fever reducer). It is a very bitter drug so the patients unable to 
take orally; hence their bitter taste were masked. ODTs Formulations were prepared by Direct Compression and wet 
granulation method by the use of superdisintegrants and taste masking (F7;F8) is done by Eudragit EPO. The developed 
formulations were evaluated in terms of weight variation, drug content, friability, thickness, hardness, disintegration and in 
vitro dissolution test. Stability study of optimized formulation was also carried out as per ICH guidelines. The effects of 
disintegrants as well as binders in different concentration on the release profile of paracetamol ODTs were studied. The 
studied parameters were found to be satisfactory for all formulations. Disintegration time for the formulations was found to 
be less than 40 seconds. Disintegration time for all ODTs decreased with increase in disintegrant concentration. ODTs 
prepared using Avicel possessed least disintegration time (11s), offered better dissolution profile than that of all the ODTs 
formulations. Accelerated studies proved that the optimized formulation was stable even after three months. 
Keywords: Orodispersible tablets, Paracetamol, Prosolv ODT; Eudragit EPO, physical characterization. in-vitro 
dissolution,   
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ODTs are beneficial for patients because of a) ease of 
administration to patients who refuse to swallow a 
tablet, such as paediatric and geriatric patients and, 
psychiatric patients, b) convenience in administration 
of drug and accurate dosing as compared to liquid 
formulations c) water is not required for swallowing 
the dosage from, which is convenient feature for 
patients who are travelling and do not have immediate 
access to water. d) good mouth feels properly of ODTs 
helps to change the basic view of medication as "bitter 
pill", particularly for paediatric patients e) fast 
dissolution of  medicament  and absorption  which will 
leads to rapid, onset of action f) some drugs are 
absorbed from the month pharynx and oesophagus as 
the saliva passes down into the stomach, in such cases 
bioavailability of drugs is increased g) It provides 
advantages of liquid formulations in the form of solid 
dosage form h) pre-gastric absorption can result in 
improved bioavailability and as a result of reduced 
dosage, improved clinical performance through a 
reduction of unwanted effects
5
. 
The centre for drug evaluation and research states an 
orally dissolving tablet to be “A dosage form 
containing medicinal substances, which disintegrates 
rapidly, usually within a matter of seconds, when 
placed upon tongue 
2” This system is recognized with 
other synonyms like fast dissolving tablets; melt in 
mouth tablets, porous tablets, rapidly disintegrating 
tablets, quick dissolving, and rapimelt tablets. Despite 
various nomenclatures the function and concept of all 
these Drug Delivery System (DDS) is similar
6
.  
To overcome the problems associated with 
conventional tablets/capsules ODTs were developed. 
Paracetamol is a widely used over-the-counter 
analgesic (pain reliever) and antipyretic (fever 
reducer). It is a very bitter drug. The main objective of 
the present work is to formulate dispersible or oro-
dispersible tablets of Paracetamol wherein its bitter 
taste is masked. Such taste masked formulations have 
been found to improve the quality of treatment in 
pediatrics patients. The oro-dispersible tablets have the 
advantage that they can be swallowed without water. 
They increase the patient compliance as well as 
provide quicker onset of action
7
.  In these cases, the 
bioavailability of drugs from these formulations might 
be greater compared to the conventional oral dosage 
forms. This creates porous structure and results in rapid 
disintegration 
8
. Basic approaches to develop 
dispersible tablet include maximizing the porous 
structure of the tablet matrix, incorporating the 
appropriate disintegrating agent and using highly water 
soluble excipients in the formulation, dispersible tablet 
can be achieved by various direct compression and wet 
granulation technique. Superdisintegrants are generally 
used at a low level in the solid dosage form, typically 1 
– 10 % by weight relative to the total weight of the 
dosage unit. Various synthetic disintegrants like 
microcrystalline cellulose, crosspovidone, 
crosscarmellose sodium, sodium starch glycolate have 
been used in the formulation of fast dissolving 
tablets
9
.PROSOLV ODT is a choice due to high 
functionality excipient for orally disintegrating tablet 
formulation Smooth and creamy mouthfeel, Excellent 
flowability, Superior compaction profile when 
compared to other matrices, Excellent blending 
characteristics for improved content uniformity, High 
patient compliance 
10
. Crosspovidone CL, the cross- 
linked PVP, is not only one of the three “super-
disintegrants”. Moreover, Crosspovidone  CL accel-
erates the dissolution and the bioavailability due to its 
power to form complexes with many insoluble 
actives.Taste masking by polymer coating
 
has been 
widely used techniques for taste masking of drug 
11
. 
Thus, by considering aforesaid mentioned advantages; 
authors decided to develop taste masked oro-
dispersible tablets of Paracetamol.  
MATERIALS AND METHODS 
Materials 
Paracetamol was obtained as a gift sample from 
Biocon, Bangalore. Micro crystalline cellulose/Avicel 
PH 102(diluent) was obtained from PMC polymers. 
Crosspovidone (super disintegrant), and magnesium 
stearate (glidant) were obtained from Signet chemicals 
Pvt. Ltd. India. Eudragit EPO was obtained from 
Evonik, Mumbai, Sodium carbonate (Rankem), 
Acesulfame potassium (sweetener) was obtained from 
Nutrinova. Orange flavour was obtained from Kerry 
bioscience. All other chemicals used were of analytical 
grade. 
 Methods: 
Drug-excipient compatibility study were done by 
using Differential scanning calorimetry (DSC): DSC- 
60 Shimadzu, Japan was used to check the physical, 
chemical and biological characteristics of drug 
substance alone and its combination with various 
formulation excipients used in the final product. The 
samples were placed in a sealed aluminium pans and 








Direct Compression Method (Batch F1 to F4): 
Weigh and sift the dry complex, passed through 30 
#sieves. Paracetamol, Diluents (Mannitol, Avicel PH 
102) and superdisintegrant (Crospovidone CL), 
through 40# sieve and Colloidal Silicon Dioxide, 
Sweeten, Flavors, Lubricant through 60# sieve. Mix all 
the ingredient in poly begs for 5 min. Lubricated blend 
were compressed into tablets using 12mm FFBE (Flat 




Wet Granulation Method (Batch F5 to F6): Weigh 
and sift Paracetamol, Diluents (Mannitol, MCC) and 
superdisintegrant (Croscarmellose Sodium, 
Crospovidone CL) through 40# sieve. Then, 
Paracetamol and diluents were mixed in octagonal 
blender for 5 minutes. Then, Dissolve the binder (PVP 
K30) into pure water (approximately 25%). Now 
slowly add above binder solution into the mix powder 
in Rapid Mixer Granulator. Now allow to dry the 
obtained granules into a tray dryer for around 2 hr at 
60˚C. Pass the drying granules through 20# sieve. 
Weigh and sift Colloidal Silicon Dioxide, Sweetener, 
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Flavors, and Lubricant through 60# sieve. Mix all 
ingredients in poly beg for 5 minutes. Lubricated 
granules were compressed into tablets using 12mm 
FFBE (Flat Face Bevel Edge) punch set using an eight 
station tablet press.  
Coating (Batch F7 to F8): Coating of the dry granules 
with Eudragit EPO were done in GPCG (Glatt Powder 
Coater Granulator). Weigh and sift Colloidal Silicon 
Dioxide, Sweetener, Flavors, and Lubricant through 
60# sieve. Mix all ingredients in poly beg for 5 
minutes. Lubricated granules were compressed into 
tablets using 12mm FFBE (Flat Face Bevel Edge) 
punch set using an eight station tablet press. 
 
                                        Table 1: Composition of ODTs batches From F1 to F8 
Sr  Ingradient     F1 F2 F3 F4 F5 F6 F7 F8 
1 Paracetamol 250 250 250 250 250 250 - - 
2 Eudragit EPO Coated Paracetamol granules - - - - - - 400 400 
3 Prosolv ODT 227.5 127.5 - 25 - 25 - 35 
4 Avicel PH 102 - 100 100 100 100 100 25 25 
5 PVP K30 - - 25 25 25 25 - - 
6 Crospovidon CL - - 25 - 25 - 35 - 
7 Mannitol - - 55 55 55 55 - - 
8 Colloidal Silicon Dioxide - - 5 5 5 5 5 5 
9 Aspartame 10 10 25 25 25 25 15 15 
10 Orange 10 10 10 10 10 10 15 15 
11 Magnesium Stearate 2.5 2.5 5 5 5 5 5 5 
12 Purified water Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. Q.S. 




The prepared oro-dispersible tablets were characterized 
for their physicochemical properties, the methods are 
discussed along with disintegration time and drug 
dissolution characteristics as discussed below; 
Weight variation: 20 tablets were randomly selected 
from the prepared batches and their average weight was 
calculated using a digital balance. Individual weight of 




Hardness/Crushing Strength: Erweka hardness tester 
was used to determine the tablet hardness for all the 
formulated batches. The limit is toward the lower range 
in order to help early disintegration in mouth. It is the 
tensile strength of tablets expressed in kg/cm
2
. It is the 




Friability: Friability is related to the ability of tablet to 
withstand both shocks and abrasion without crumbling 
during manufacturing, packing, transportation and 
consumer handling. Friability can be evaluated by 
means of friability test apparatus (The Roche 
friabilator). In all aspect, the range is within limit of 
0.1%-0.9% are generally considered acceptable 
14
.  
Thickness: Vernier calliper was used to determine the 
thickness of the prepared tablets. 20 tablets were 
randomly selected from each trial batch and were 
measured by placing the tablet between the anvils and 
knob was rotated until the two edges of anvil touch the 
tablet and the reading was noted 
15
. 
Drug content: 20 tablets were randomly selected   
from the prepared batch and triturated to get fine 
powder. 100mg of the powder was taken and dissolved 
in 100 mL of phosphate buffer. Absorbance was noted 
spectrophotometrically at 243nm. Accordingly drug 
content was calculated 
16
. 
In vitro Disintegration test: The in-vitro disintegration 
time was determined by disintegration test apparatus. 
The time for disintegration of orodispersible tablets is 
generally <1 min and actual disintegration time that 
patient can experience ranges from 5 to 30 s. It is 
expected that disintegration test for orodispersible 
tablets should mimic disintegration in mouth within 
salivary contents. The various ODT formulations 
prepared by direct compression as well as wet 
granulation method are subjected to disintegration 
studies using 900ml water (as a disintegrating medium) 
and the time taken for disintegration is noted. To 




In vitro Dissolution test: Dissolution studies were 
conducted to determine the release pattern of the drug 
from the product.
 
Dissolution test for paracetamol was 
carried out as per USP method for dissolution test for 
tablets and capsules using apparatus II (paddle type). 
900ml of Phosphate buffer pH 5.8 was used as 
dissolution medium, and the paddle was rotated at 50 
rpm for 1 hr at a temperature of 37 ±5 
0
C. Sampling 
was done at regular intervals and was replaced by pH 
5.8 phosphate buffer after each sampling interval. 
These Samples were filtered and diluted. Absorbance 
of the resulting solution was measured at 243.0 nm 
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Percent drug release was calculated. The samples are 
then analysed spectrophotometrically at 243 nm 
15, 18
 . 
Stability studies: Stability is defined as the ability of a 
particular drug or dosage form in a specific container to 
remain within its physical, chemical, therapeutic, and 
toxicological specifications. Drug decomposition or 
degradation occurs during storage, because of chemical 
alteration of the active ingredients or due to product 
instability, lowering the concentration of the drug in the 
dosage form. The stability study indicates that the 
formulation is quite stable at different conditions of 
storage. Accelerated stability studies carried out at 
40°C ± 2°C/75% RH ± 5% RH for 3 months. The 
optimized formulation F5 was stored in aluminum 
capped clear glass vials and was subjected to a storage 
condition for 3 months in humidity chamber.  The 
samples were withdrawn at time intervals of 0, 1, 2, 3 
months and evaluated for hardness, friability, 




RESULT & DISCUSSION 
The pure drug and the optimized Formulation were 
subjected to the compatibility studies, using 
Differential Scanning Calorimetry (DSC) which is 
shown below in figure. The thermograms of mixtures 
showed no appreciable change in the melting 
endotherms of the optimized formulation as compared 
to pure drug (169.7
0
C) indicating absence of any 
interaction. API was confirmed by DSC by keeping the 
heating rate of 1ºC/min. The thermogram of API 
exhibited sharp endothermic peak with onset temp 
165.65 ºC and peak temp 169.62ºC as shown in figure. 
 
                         
                                                               Figure 1: DSC studies of the pure drug 
                
Figure 2: DSC studies of optimized formulation (F8) 
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The DSC thermograms of drug-polymer complex are 
shown in figure 2. The thermogram of drug-polymer 
exhibited sharp endothermic peak with onset temp 
143.05 ºC and peak temp 168.60ºC.This indicates the no 
interaction between drug-polymer complexes.  
       
Table 2: Physical Parameter of batch F1 to F8 












F1 499 3.96± 0.01  98.89 0.34 5.54±0.15 
F2 499 3.99± 0.12  100.56 0.31 5.48±0.41 
F3 500 3.94± 0.04  98.64 0.25 5.34±0.01 
F4 499 4.05± 0.08  98.23 0.28 5.46±0.09 
F5 496 3.89± 0.02  100.48 0.24 5.49±0.05 
F6 496 4.09± 0.19  99.75 0.18 5.37±0.02 
F7 499 3.73± 0.14  101.58 0.27 5.86±0.02 
F8 502 3.88± 0.1  101.11 0.21 5.02±0.06 
   
 
Total eight formulations (F1-F8) were prepared using 
various ingredients and two different 
superdisintegrants (Prosolv ODT; Crospovidon CL) 
was utilized with various concentrations. ODTs were 
prepared by direct compression method and wet 
granulation method and evaluated for Hardness, weight 
variation, friability, Thickness, content uniformity, 
disintegration time and dissolution.  
Weight variation of formulated batches F1 to F8 was 
shown to be within the acceptable limits i.e., 500±5 
mg. The drug content was found to be uniform for all 
the prepared formulations and was found to be 
100.3%. The % drug content was found in the range of 
98.89 - 101.58% (within the acceptable range) and the 
hardness was found between 3.73 - 4.09 kg/cm
2
. 
Thickness of ODTs was found in between 2.37-2.86 
mm. Friability of was found below 1% indicating good 
resistance against mechanical shear (Table-3). Among 
the different formulations,  
The hardness of tablets was found to be 3.73 to 4.09 
kg/cm
2
. The formulations containing low concentration 
of disintegrants have shown maximum hardness so 
they shows less % friability and it was found that 
hardness was increased with decrease in the proportion 
of concentration of disintegrants. The lowest hardness 
was obtained in formulations containing high 
disintegrants concentration and shows % friability just 
near to the limit. All the tablet shows % friability in the 
range of 0.1-0.3 % which is within the limit. All the 
formulations pass the weight variation test as all tablets 
within the range limit for weight variation.  
F- 7 was chosen as optimized batch containing 
crosscarmellose sodium as superdisintegrant, as it has 
produced the ODT having least disintegration time of 
11 sec. The dissolution study was carried out in SSF, 
yielding about 70% and 90% dissolution respectively 
in 10 minutes. These results showed that taste masking 
was also effective. On the basis of above results it can 
be concluded that an oral disintegrating tablet of 
Paracetamol can be prepared using superdisingrates. 
Eudragit EPO also found to be efficient in taste-
masking. From the disintegration test, (F7) has lower 
disintegration time (11 seconds). Drug release profile 
of all prepared immediate release tablets was shown in 
fig.1.Based on the dissolution data of all the prepared 
ODTs, the F7 and F8 batch shows 99.6 % drug release 
whthin 10 minutes.  Formulations found to be stable 
for three month when tested for its in vitro dissolution 
studies (98.2% release at the end of 20 minutes), which 
were evident of stability of the product. The 
dissolution curves show that Crospovidon CL has the 
best performance, followed by Prosolv ODT (F8). The 
drug release from FDTs increased with increasing 
concentration of superdisintegrants and was found to 
be highest with formulations containing 
crosspovidone. In some cases customers may wish to 
have a slightly slower disinter-gration for specific 
applications; the new materials prosolv could help to 
produce a dissolution profile fitted to such a 
requirement, e. g. for generics; which further enhances 
taste as creamy mouth feel. Formulations found to be 
stable for three month when tested for its in vitro 
dissolution studies (98.2% release at the end of 30 
minutes), which were evident of stability of the 
product. 
 












F1 F2 F3 F4 F5 F6 F7 F8 
Disintegrating Time (Sec) 
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Table 4: Dissolution study of Batch F1 to F8 
Time 
(min) 
% Drug Release in 900ml P
H 
5.8 phosphate buffer 50 RPM, 37°C ± 
0.1°C,                    USP Type II (Paddle) 
F1 F2 F3 F4 F5 F6 F7 F8 
0 0 0 0 0 0 0 0 0 
2 22.35 24.27 27.22 21.41 18.94 26.34 22.94 19.54 
4 28.48 31.45 40.72 38.42 37.26 34.86 58.11 33.42 
6 36.49 46.22 56.49 49.65 46.49 51.28 71.29 50.11 
8 45.24 53.84 7015 64.23 68.64 66.48 80.78 64.54 
10 61.41 72.45 84.21 79.12 79.98 81.12 95 79.65 
12 76.49 84.61 96.48 86.43 98.49 88.34  88.21 
14 85.37 91.28  94.28  92.49  95.68 
16 93.82 97.89       
   
 
 
Figure 4: Dissolution profile of batch F1 to F8 
CONCLUSION: 
Oro-dispersible tablets have precious advantages over 
conventional solid dispersible dosage form. By the use 
of Prosolv it makes the tablets creamy mouth feels but 
not disintegrate with least time as compared to 
Crospovidon CL.  This drug delivery (ODTs) is one of 
the great innovations of all the novel drug-delivery 
systems. By formulating oro-dispersible tablets it 
disintegrates within 30 sec hence dissolution process is 
improved, further solubility is enhanced. As such 
absorption is directly proportional to solubility of drug, 
and furthermore the bioavailability is also increased. So 
this drug delivery will improve patient compliance, 
convenience for administration of bitter drugs, 
bioavailability, and rapid onset of action. However, 
ordinary people are not much conscious of this delivery 
system. Therefore, pharmacists should inform to the 
patient regarding this system. It is the job of the 
pharmacist to advice the patients about use, advantages, 
storage and maintenance of product. The developed 
formulations ODTs should be handled carefully because 
they do not have sufficient mechanical strength. Patients 
who suffer from dryness of mouth should not be 
prescribed oro-dispersible tablets, since minimum 
volume of saliva is necessary for it to 
disintegrate/dissolution. Oro-dispersible formulations 
are very much suitable for pediatrics having no primary 
teeth and for geriatric patients who lost their teeth 
permanently.  
Thus, in near future, it is expected that this delivery 
system ODTs will get huge importance as that of 
conventional delivery.                
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